Drug Patent Disclosure Act

Summary#

This bill would require drug and biologic developers to share, and certify consistency of, certain information they send to the Food and Drug Administration (FDA) with the United States Patent and Trademark Office (USPTO). It also creates a new defense in patent-infringement lawsuits when a patent owner negligently or intentionally failed to make required disclosures.

• Main change: Sponsors of new drug applications and holders of approved drugs or licensed biologics must submit to the USPTO any information that is “material to patentability” that they submitted to the FDA, and must certify that information given to each agency is consistent.
• Who must act: Drug and biologic applicants, holders of approved applications or licenses, and the USPTO and FDA (which must update procedures).
• Enforcement: Failing to submit the required certification is added to the list of prohibited acts under the drug law (making it an FDA enforcement matter). The bill also gives accused infringers a legal defense if a patent owner negligently or intentionally failed to disclose required information.
• Scope and timing: Rules apply to new applications filed on or after enactment. For older applications, the requirements apply mainly to patents issued or submissions made after enactment.
• Confidentiality: The USPTO must treat information it receives under this rule as if it were confidential trade secrets or financial information held by the FDA.

What is unclear: the bill leaves open how agencies will define “material to patentability” in practice, how FDA enforcement will be carried out, and what penalties (if any) will follow from the added prohibited act beyond existing enforcement tools.

What it means for you#

• Pharmaceutical and biotech companies (sponsors and patent holders):

  • Must prepare and submit extra materials to the USPTO that match what they gave the FDA when that material could affect patentability.
  • Must provide certifications about consistency between FDA and USPTO submissions.
  • Could face FDA enforcement actions if they fail to provide required certifications.
  • May need new internal processes to track what was told to each agency.

• Generic and biosimilar manufacturers:

  • Could use the new non-disclosure defense in patent litigation if a patent owner failed to make required disclosures; this may affect the strength of some infringement claims.
  • May gain access (indirectly, via litigation) to arguments that a patent should not have been granted.

• USPTO and FDA:

  • Must update rules and procedures to accept and protect information coming from the other agency.
  • Will have added work to process certification statements and new submissions.

• Patients and prescribers:

  • The bill does not directly change drug approval standards, pricing, or prescribing. Any downstream effects (for example, on patent disputes or generic entry) would be indirect and depend on how the new rules are applied.

• Courts and litigants:

  • Patent litigation over drug patents may change because of the new defense tied to failures to disclose required information.

Expenses#

No publicly available information.

• The bill does not include a fiscal note in the supplied material.
• Possible costs (not estimated in the bill): additional staff time and legal work for drug companies to prepare certifications and submit information; administrative and IT updates and rulemaking costs for the USPTO and FDA; potential changes in litigation costs for both patent owners and challengers.
• The bill requires the USPTO to update regulations or procedures. That is likely to carry agency implementation costs, but no dollar amounts are provided.

Proponents' View#

• The bill appears intended to increase transparency between what drug developers tell the FDA and what they tell the USPTO about patents and data that support approval.
• A possible argument for the bill is that sharing FDA submissions with the USPTO could reduce the chance that patents are granted based on incomplete or inconsistent information.
• Supporters may view the non-disclosure defense as a tool to discourage withholding of information that could affect whether a patent should have been issued.
• The confidentiality requirement for the USPTO attempts to protect trade secrets and sensitive financial information even when shared.

Opponents' View#

• One concern is added administrative burden on drug and biologic companies to prepare, certify, and track duplicated submissions to two agencies.
• The bill does not clearly define “material to patentability” until the USPTO issues regulations. That vagueness could create uncertainty for companies and courts.
• Even with required confidentiality protections, companies may worry about exposing sensitive manufacturing or analytical data to a second agency and about accidental disclosure in litigation.
• The new defense in patent cases may increase litigation or weaken existing patents in ways that are hard to predict.
• It is unclear how FDA enforcement will apply in practice and what penalties follow from the new prohibited act beyond existing remedies.